Impact ledger
Onco360 (ONCS): the developments shaping its investment case
Follow the evidence affecting Onco360. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Onco360 · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-08-27 · 2 reports
FDA Approves Revolution Medicines RASONQUE in Pancreatic Cancer
Channel: Increased prescription volume and dispensing fees from being the national specialty dispensing partner for a newly approved oncology drug.
Bullish· 1-3m
Event impact log
2 events mapped to ONCS since 2026-08-27. Evidence through 2026-08-27.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-08-27 | FDA Approves Revolution Medicines RASONQUE in Pancreatic Cancer | Increased prescription volume and dispensing fees from being the national specialty dispensing partner for a newly approved oncology drug. | Bullish | 1-3m | 0.60 |
| 2026-08-27 | FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer | Increased dispensing volume and revenue from being appointed as the national specialty dispensing partner for RASONQUE. | Bullish | 1-3m | 0.60 |
Continue this research
Build your Onco360 investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the ONCS entity page →